Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with AATD

TSRA-196 is designed to precisely correct the genetic mutation underlying AATD, with the goal of restoring production of functional alpha-1 antitrypsin (AAT) protein through a one-time, durable ...
Rutland Herald

Amphastar Announces FDA Approval for Ipratropium Bromide HFA

RANCHO CUCAMONGA, CA / / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and ...
Pulmonology Advisor

CT-Based Severity Scoring System, Elastic PRM, Predicts COPD Advancement

Elastic parametric response mapping (ePRM), a CT-based severity scoring system for regional lung volumes, can monitor COPD progression.

Amphastar Pharmaceuticals, Inc.: Amphastar Announces FDA Approval for Ipratropium Bromide HFA

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbre ...

Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines

Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by SERPINA1 gene mutations, leading to conditions like pulmonary emphysema and liver dysfunction. The AATD market is in its ...

Nanoform Finland Oyj: Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe

Nanoform Finland Plc | Company Release | February 26, 2026 at 08:10:00 EET Product kernel strategy continues to gain traction. Nanoenzalutamide: pivotal human fed and fasted study concluded, three mor ...

Murderer likely to die in jail after killing ex-wife in 'furious attack'

A man who murdered his ex-wife in a "furious attack" is likely to die in jail after being sentenced to a total of 20 years behind bars.